BARD Peripheral Vascular, Inc. Sustainability Profile
BARD Peripheral Vascular, Inc., a subsidiary of C. R. Bard, Inc., is a leading player in the medical device industry, specialising in innovative solutions for vascular access and peripheral vascular interventions. Headquartered in the United States, the company operates extensively across North America and Europe, providing critical products that enhance patient care. Founded in the early 1960s, BARD Peripheral Vascular has achieved significant milestones, including the development of advanced catheter technologies and vascular grafts. Their core offerings, such as the innovative AngioJet® Thrombectomy System and various stent systems, are distinguished by their efficacy and reliability in treating vascular diseases. With a strong market position, BARD Peripheral Vascular is recognised for its commitment to quality and innovation, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does BARD Peripheral Vascular, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BARD Peripheral Vascular, Inc.'s score of 67 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BARD Peripheral Vascular, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Becton, Dickinson and Company, which may influence its climate commitments and emissions reporting. As part of its corporate family relationship, BARD Peripheral Vascular inherits emissions data and climate initiatives from Becton, Dickinson and Company. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Becton, Dickinson and Company. However, specific reduction targets or achievements for BARD Peripheral Vascular have not been disclosed. While no absolute emissions figures are provided, the company is expected to align with the sustainability goals and climate strategies of its parent organisation, which may include commitments to reduce emissions across Scope 1, 2, and 3 categories. As such, BARD Peripheral Vascular is positioned within a broader context of corporate responsibility and climate action, although specific metrics and targets remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 96,333,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 514,801,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 158,622,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is BARD Peripheral Vascular, Inc.'s Industry?
How Carbon Intensive is BARD Peripheral Vascular, Inc.'s Location?
BARD Peripheral Vascular, Inc.'s Scope 3 Categories Breakdown
BARD Peripheral Vascular, Inc.'s Scope 3 emissions, which decreased by 6% last year and increased significantly since 2008, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 38% of Scope 3 emissions.
Top Scope 3 Categories
BARD Peripheral Vascular, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BARD Peripheral Vascular, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
